RxDoctor Payments Data

Russell Nelligan, MD

Ophthalmology · St Augustine, FLNPI 1255542767

Payments from drug & device makers

$5,817in general payments, 2019–2025

Across 207 payments — averaging $28.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • NEW World Medical,inc.$2K
  • Alcon$1K
  • Sight Sciences, Inc.$357
  • AbbVie$266
  • Biotissue Holdings Inc.$266
  • Johnson & Johnson Surgical Vision, Inc.$260
  • plus $1K from 15 others

What the payments were for

  • Consulting fees$3005%
  • Food & beverage$5,49394%
  • Education$240%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,817 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$823,459
Medicare patients
1,379
Services billed
4,573

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine88$101,387
XiidraLifitegrast31$36,432
Cyclosporine42$20,843
LumiganBimatoprost40$19,129
CombiganBrimonidine Tartrate/Timolol20$11,019
SimbrinzaBrinzolamide/Brimonidine Tart35$8,687
Latanoprost737$8,573
Prednisolone Acetate159$6,733
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol30$3,954
Travoprost19$3,805
Ketorolac Tromethamine215$3,648
Loteprednol Etabonate12$2,514
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat167$2,425
ValacyclovirValacyclovir Hcl21$1,681
Timolol Maleate133$1,523

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$266$131,534148 claims
Bausch & Lomb Americas Inc.Xiidra$97$36,43231 claims
AlconSimbrinza$1,024$8,68735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in St Augustine

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →